Hazama, S., Watanabe, S., Ohashi, M., Yagi, M., Suzuki, M., Matsuda, K., Yamamoto, T., Suga, Y., Suga, T., Nakazawa, S., and Oka, M. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res 2009;29(7):2611-2617. View abstract.
Aldwinckle J, Kristiansen B. A quality-of-life study in healthy adults supplemented with Lentinex beta-glucan of shiitake culinary-medicinal mushroom, Lentinus edodes (Agaricomycetes). Int J Med Mushrooms. 2020;22(5):407-415. View abstract.
Arinaga S, Karimine N, Takamuku K, et al. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmac 1992;14:535-539. View abstract.
Congcong Q, Hengting Z, Shuhui L, Fang Y, Shan W. Evaluation of efficacy and safety for lentinan in the control of the malignant pleural effusions via intrapleural injection. Am J Med Sci. 2019;358(6):400-411. View abstract.
Gordon M, Bihari B, Goosby E, et al. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J Med 1998;29:305-30. View abstract.
Gordon M, Guralnik M, Kaneko Y, et al. A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of
200-500/mm3. J Med 1995;26:193-207. View abstract.
Lin Y, Wei Y, Hu X, et al. Evaluation of lentinan effects on cytochrome P450 activity in rats by a cocktail method. Iran J Basic Med Sci. 2019;22(3):296-301. View abstract.
Nishihira T, Akimoto M, Mori S. [Anti-cancer effects of BRMs associated with nutrition in cancer patients]. Gan To Kagaku Ryoho,1988;15:1615-20. View abstract.
Sun J, Zhao G. Clinical effects of lentinan combined with budesonide inhalation in treating acute exacerbation of chronic obstructive pulmonary disease under mechanical ventilation. Exp Ther Med. 2019;17(3):1503-1508. View abstract.
Taguchi T. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect Prev Suppl 1987;1:333-49. View abstract.
Tari K, Satake I, Nakagomi K, et al. [Effect of lentinan for advanced prostate carcinoma]. Hinyokika Kiyo 1994;40:119-23. View abstract.
Wada T, Nishide T, Hatayama K, et al. [A comparative clinical trial with tegafur plus lentinan treatment at two different doses in advanced cancer]. Gan To Kagaku Ryoho 1987;14:2509-11. View abstract.
Wang H, Cai Y, Zheng Y, Bai Q, Xie D, Yu J. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer Med. 2017;6(10):2222-2233. View abstract.
Wang JL, Bi Z, Zou JW, Gu XM. Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Mol Med Rep. 2012;5(3):745-8. View abstract.
Xiao Z, Jiang Y, Chen XF, et al. Intrathoracic infusion therapy with lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials. Phytomedicine. 2020;76:153260. View abstract.
Yin X, Ying J, Li L, Zhang H, Wang H. A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer. Indian J Cancer. 2015;52 Suppl 1:e29-31. View abstract.
Yoshino S, Nishikawa K, Morita S, et al. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016;65:164-71. View abstract.
Yoshiyuki T, Onda M, Tokunaga A, et al. [Treatment for peritoneal dissemination of gastric cancer by intraperitoneal administration of CDDP through Infuse-a-Port]. Gan To Kagaku Ryoho 1994;21:2323-5. View abstract.
Zhang D, Zheng J, Ni M, et al. Comparative efficacy and safety of Chinese herbal injections combined with the FOLFOX regimen for treating gastric cancer in China: a network meta-analysis. Oncotarget. 2017;8(40):68873-68889. View abstract.